CPA
HOWL icon

Capital Performance Advisors’s Werewolf Therapeutics HOWL Stock Holding History

Capital Performance Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60
Closed -$127 – 1266
2024
Q3 		$127 Buy
+60
New +$136 ﹤0.01% 2655

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Capital Performance Advisors's HOWL Position: Q4 2024 in Review

Capital Performance Advisors sold out of Werewolf Therapeutics (HOWL) in Q4 2024, closing a stake of 60 shares — an estimated $127 sold.

Capital Performance Advisors first reported a position in HOWL in Q3 2024 and held it in 1 quarter. The position peaked at $127 in Q3 2024. 73 funds tracked by Wall St. Rank hold HOWL as of Q4 2024.

  • Capital Performance Advisors reported no remaining Werewolf Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 60 Werewolf Therapeutics shares in Q4 2024, an estimated $127.
  • Capital Performance Advisors first reported a position in Werewolf Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Werewolf Therapeutics position peaked at $127 in Q3 2024.
  • 73 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.